Future directions for allergen immunotherapy

Journal of Allergy and Clinical Immunology

Volumn 102, Issue 3, 1998, Pages 335-343

  Platts Mills, Thomas A E ^a,b   Mueller, Geoffrey A ^a   Wheatley, Lisa M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

DNA vaccines; Immunotherapy; Peptides; Recombinant allergens

Indexed keywords

ALLERGEN; ALUMINUM POTASSIUM SULFATE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; DNA VACCINE; FREUND ADJUVANT; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PEPTIDE; PLASMID VECTOR; RECOMBINANT PROTEIN; TETANUS TOXOID; TYROSINE DERIVATIVE;

ADJUVANT THERAPY; ALLERGIC DISEASE; AMINO ACID SEQUENCE; ANTIBODY RESPONSE; DELAYED HYPERSENSITIVITY; GENE TARGETING; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNIZATION; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOTHERAPY; MOLECULAR CLONING; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS;

EID: 0031657626     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(98)70117-4     Document Type: Article

References (73)

1. Noon L. Prophylactic inoculation for hay fever. Lancet 1911;1:1572.
2. Prausnitz C, Kustner H. Studien veber die verbering findlichkeit. Zentrabl Bakteiol Parasitenk Infectionskr Hyg Abt 1921;1:86,160.
3. Cooke RA, Barnard J, Hebald S, Stull A. Serological evidence on immunity with co-existing sensitization in a type of human allergy, hay fever. J Exp Med 1935;62:733-50.
4. Ishizaka K, Ishizaka T, Hornbrook MM. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 1966;97:75-85.
5. Platts-Mills TAE. Local production IgG, IgA and IgE antibodies in grass pollen hay fever. J Immunol 1979;122:2218-25.
6. Rawle FC, Mitchell EB, Platts-Mills TAE. T cell responses to the major allergen from the house dust mite Dermatophagoides pteronyssinus, Antigen PI: comparison of patients with asthma, atopic dermatitis, and perennial rhinitis. J Immunol 1984;133:195-201.
7. Rocklin RE, Sheffer AL, Greineder DK, Melmon KL. Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 1980;302:1213-9.
8. Gatien JG, Merler E, Colten HR. Allergy to ragweed antigen E: effect of specific immunotherapy on the reactivity of human T lymphocytes in vitro. Clin Immunol Immunopathol 1975;4:32-7.
9. Sale SR, Patterson R. Immunotherapy. In: Korenblat PE, Wedner HJ, editors. Allergy theory and practice. 2nd ed. Philadelphia: W.B. Saunders Company; 1992. p 279-94.
10. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996;97:1356-65.
11. Till S, Walker S, Dickason R, Huston D, O'Brien F, Lamb J, et al. IL-5 production by allergen-stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis. Clin Exp Immunol 1997;110:114-21.
12. Wierenga EA, Snoek M, DeGroot C, Chretien I, Bos JD, Jansen HM, et al. Evidence for compartmentalization of functional subsets of CD4+ lymphocytes in atopic patients. J Immunol 1990;144:4651-6.
13. Romagnani S. Type l T helper and type 2 T helper cells: functions, regulation, and role in protection and disease. Int J Clin Lab Res 1991;21:152-68.
14. Aalberse RC, van Milligen F, Tan KY, Stapel SO. Allergen specific IgG4 in atopic disease. Allergy 1993;48:559-69.
15. Rowntree S, Platts-Mills TAE, Cogswell JJ, Mitchell EB. A subclass IgG4-specific antigen-binding radioimmunoassay (RIA). J Allergy Clin Immunol 1987;80:622-30.
16. Bressler RB, Lesko J, Jones ML, Wasserman M, Dickason RR, Huston MM, et al. Production of IL-5 and granulocyte-macrophage colony-stimulating factor by naive human mast cells activated by high-affinity IgE receptor ligation. J Allergy Clin Immunol 1997;99:508-14.
17. Holt PG. A potential vaccine strategy for asthma and allied atopic diseases during early childhood. Lancet 1994;344:456-8.
18. Sitz KV, Loomis-Price LD, Ratto-Kim S, Kenner JR, Sau P, Eckels KH, et al. Delayed type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons. J Infect Dis 1997;176:1085-9.
19. Woodfolk JA, Slunt JB, Deuell B, Hayden ML, Platts-Mills TAE. Definition of a Trichophyton protein associated with delayed hypersensitivity in humans: evidence for immediate (IgE and IgG4) and delayed hypersensitivity to a single protein. J Immunol 1996;156:1695-701.
20. Marsh DG. Allergens and the genetics of allergy. In: Sela M, editor. The antigens. Vol III. New York: Academic Press; 1975. p 271-360.
21. Hayglass KT, Stefura WP. Anti-IFNγ treatment blocks the ability of glutaraldehyde polymerized allergens to inhibit specific IgE responses. J Exp Med 1991;173:279-87.
22. Ishizaka K, Kishimoto T, Delespesse G, King TP. Immunogenic properties of modified antigen E. I. Presence of specific determinants for T cells in denatured antigen and polypeptide chains. J Immunol 1974;113:70-7.
23. Hendrix SG, Patterson R, Zeiss CR, Suszko IM. Further studies on the safety of polymerized antigens for immunotherapy. J Allergy Clin Immunol 1981;67:124-8.
24. Juniper EF, O'Connor J, Roberts RS, Evans S, Hargreave FE, Dolovich J. Polyethylene glycol-modified ragweed extract: comparison of two treatment regimens. J Allergy Clin Immunol 1986;78:851-6.
25. Frankland AW, Augustin R. Prophylaxis of summer hay fever and asthma: controlled trial comparing crude grass pollen extracts with isolated main component. Lancet 1954;1:1055.
26. Platts-Mills TAE, von Maur RK, Ishizaka K, Norman PS, Lichtenstein LM. IgA and IgG anti-ragweed antibodies in nasal secretions. J Clin Invest 1976;57:1041-50.
27. Dannemann A, van Ree R, Kulig M, Bergmann RL, Bauer P, Forster J, et al. Specific IgE and IgG4 immune responses to tetanus and diphtheria toxoid in atopic and nonatopic children during the first two years of life. Int Arch Allergy Immunol 1996;111:262-7.
28. Chapman MD, Rowntree S, Mitchell EB, Di Prisco de Fuenmajor MC, Platts-Mills TAE. Quantitative assessments of IgG and IgE antibodies to inhalant allergens in patients with atopic dermatitis. J Allergy Clin Immunol 1983;72:27-33.
29. Elsayed S, Apold J. Immunochemical analysis of codfish allergen M: localization of immunoglobulin binding sites as demonstrated by native and synthetic peptides. Allergy 1983;38:449-55.
30. Mole LE, Goodfriend L, Lapkoff CB, Kehoe JM, Capra JD. The amino acid sequence of ragweed pollen allergen Ra5. Biochemistry 1975;14:1216-20.
31. Chua KY, Stewart GA, Thomas WR, Simpson RJ, Dilworth RJ, Plozza TM, et al. Sequence analysis of cDNA coding for a major house dust mite allergen, Der p I: homology with cysteine proteases. J Exp Med 1988;167:175-82.
32. Tovey ER, Johnson MC, Roche AL, Gobon GS, Baldo BA. Cloning and sequencing of a cDNA expressing a recombinant house dust mite protein that binds human IgE and corresponds to an important low molecular weight allergen. J Exp Med 1989;170:1457-62.
33. Arruda LK, Vailes LD, Platts-Mills TAE, Hayden ML, Chapman MD. Induction of IgE antibody responses by Glutathione-S-transferase from the German cockroach (Blattella germanica). J Biol Chem 1997;272:20907-12.
34. Morgenstern JP, Griffith U, Brauer AW, Rogers BL, Bond JF, Chapman MD, et al. Amino acid sequence of Fei d I, the major allergen of the domestic cat: protein sequence analysis and cDNA cloning. Proc Natl Acad Sci USA 1991;88:9690-4.
35. Chua KY, Doyle CR, Simpson RJ, Turner KJ, Stewart GA, Thomas WR. Isolation of cDNA coding for the major mite allergen Der p II by IgE plaque immunoassay. Int Arch Allergy appl Immunol 1990;91:118-23.
36. Godnic-Cvar J, Susani M, Breiteneder H, Berger A, Havelec L, Waldhor T, et al. Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity reactions equal to those induced by natural Bet v l in the airways of patients allergic to tree pollen. J Allergy Clin Immunol 1997;99:354-9.
37. Woodfolk JA, Slunt JB, Deuell B, Hayden ML, Platt-Mills TAE. Definition of a Trichophyton protein associated with delayed hypersensitivity in humans: evidence for immediate (IgE and IgG4) and delayed hypersensitivity to a single protein. J Immunol 1996;156:1695-701.
38. Valenta R, Duchene M, Pettenburger K, Sillaber C, Valent P, Bettelheim P, et al. Identification of profilin as a novel pollen allergen: IgE autoreactivity in sensitized individuals. Science 1991;253:557-60.
39. Stewart GA, Thompson PJ. The biochemistry of common aeroallergens. Clin Exp Allergy 1995;25:1020-44.
40. Hewitt CRA, Brown AP, Hart BJ, Pritchard DI. A major house dust allergen disrupts the immunoglobulin E network by selectively cleaving CD23: innate protection by antiproteases. J Exp Med 1995;182:1537-44.
41. Comoy EE, Pestel J, Duez C, Stewart GA, Vendeville C, Fournier C, et al. The house dust mite allergen, Dermatophagoides pteronyssinus, promotes type 2 responses by modulating the balance between IL-4 and IFN-γ. J Immunol 1998;160:2456-62.
42. Norman PS, Ohman JL, Long AA, Creticos PS, Gefter ML, Shaked Z, et al. Follow up study of the first clinical trial with T cell defined peptides from cat allergen Fel d 1 [abstract]. J Allergy Clin Immunol 1995;95:259.
43. Creticos PS, Hebert J, Philip G, the Allervax Ragweed Study Group. Efficacy of Allervax ragweed peptides in the treatment of ragweed-induced allergy [abstract]. J Allergy Clin Immunol 1997;99:401.
44. Norman PS, Ohman JL, Long AA, Creticos PS, Gefter ML, Shaked Z, et al. Treatment of cat allergy with T cell reactive peptides. Am J Respir Crit Care Med 1996;154:1623-8.
45. Hoyne GF, Kristensen NM, Yssel H, Lamb JR. Peptide modulation of allergen-specific immune responses. Curr Opin Immunol 1995;7:757-61.
46. Suzuki G, Kawase Y, Koyasu S, Yahara I, Kobayashi Y, Schwartz RH. Antigen-induced suppression of the proliferative response of T cell clones. J Immunol 1988;140:1359-67.
47. Hetzel C, Lamb JR. CD4+ T cell-targeted immunomodulation and the therapy of allergic disease. Clin Immunol Immunopathol 1994;73:1-10.
48. Cwirla SE, Peters EA, Barrett RW, Dower WJ. Peptides on phage: a vast library of peptides for identifying ligands. Proc Natl Acad Sci USA 1990;87:6378-82.
49. Ferreira F, Hirthenlehner K, Briza P, Breiteneder H, Scheiner O, Kraft D, et al. Isoforms of atopic allergens with reduced allergenicity but conserved T cell antigenicity: possible use for specific immunotherapy. Int Arch Allergy Immunol 1997;113:125-7.
50. Thomas WR, Smith W, Hales BJ, Carter MD. Functional effects of polymorphisms of house dust mite allergens. Int Arch Allergy Immunol 1997;113:96-8.
51. Chua KY, Huang CH, Shen HD, Thomas WR. Analysis of sequence polymorphism of a major mite allergen, Der p 2. Clin Exp Allergy 1996;26:829-37.
52. Smith AM, Chapman MD. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol Immunol 1996;33:399-405.
53. Smith AM, Chapman MD, Taketomi EA, Platts-Mills TAE, Sung SSJ. Recombinant allergens for immunotherapy: a Der p 2 variant with reduced IgE reactivity retains T cell epitopes. J Allergy Clin Immunol 1998;101:423-5.
54. Smith AM, Chapman MD. Localization of antigenic sites on Der p 2 using oligonucleotide-directed mutagenesis targeted to predicted surface residues. Clin Exp Allergy 1997;27:593-9.
55. Ichikawa S, Hatanaka H, Yuuk T, Iwamoto N, Kojima S, Nishiyama C, et al. Solution structure of Der f 2, the major mite allergen for atopic diseases. J Biol Chem 1998;273:356-60.
56. Mueller GA, Smith AM, Hakkaart GAJ, Aalberse RC, Chapman MD, Rule GS, et al. Expression and secondary structure determinauon by NMR methods of the major house dust mite allergen Der p 2. J Biol Chem 1997;272:26898-908.
57. Mueller GA. The molecular and antigenic structure of the major house dust mite allergen, Der p 2 [thesis]. University of Virginia; 1998.
58. S later JE, Vedvick T, Arthur-Smith A, Trybul DE, Kekwick RG. Identification, cloning, and sequence of a major allergen (Hev b 5) from natural rubber latex (Hevea brasiliensis). J Biol Chem 1996;271:25394-9.
59. Burks AW, Cockrell G, Connaughton C, Karpas A, Helm RM. Epitope specificity of the major peanut allergen, Ara h II. J Allergy Clin Immunol 1995;95:607-11.
60. Hsu CH, Chua KY, Tao MH, Lai YL, Wu HD, Huang SK, et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996;2:540-4.
61. RazE, Tighe H, Sato Y, Corr M, Dudler JA, Roman M, et al. Preferential indication of aTh1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996;93:5141-5.
62. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273:352-4.
63. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, et al. Immunostimulatory DNA sequences function as T helper-1-promoung adjuvants. Nat Med 1997;3:849-54.
64. Shirakawa T, Enomoto T, Shimazu S, Hopkins JM. The inverse association between tuberculin responses and atopic disorder. Science 1997;275:77-9.
65. Cookson WO, Moffatt MF. Asthma: An epidemic in the absence of infection? Science 1997;275:41-2.
66. Holt PG. A potential vaccine strategy for asthma and allied atopic diseases during early childhood. Lancet 1994;344:456-8.
67. Dold S, Wjst M, von Mutius E, Reitmeir P, Stiepel E. Genetic risk for asthma, allergic rhinitis, and atopic dermatitis. Arch Dis Child 1992;67:1018-22.
68. Nyce JW, Metzger WJ. DNA antisense therapy for asthma in an animal model. Nature 1997;385:721-5.
69. Rempel JD, Wang MD, Hayglass KT. In vivo IL-12 administration induces profound but transient commitment to Th1-associated patterns of cytokine and antibody production. J Immunol 1997;159:1490-6.
70. Reid MJ, Moss RB, Hsu YP, Kwasnicki JM, Commerford TM, Nelson BL. Seasonal asthma in Northern California: allergic causes and efficacy of immunotherapy. J Allergy Clin Immunol 1986;78:590-600.
71. Creticos PS, Reed CE, Norman PS, Khoury J, Adkinson NF Jr, Buncher CR, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996;334:501-6.
72. Graft DF, Valentine MD. Immunotherapy. In: Kaplan AP, editor. Allergy. New York: Churchill Livingstone; 1985. p 679-92.
73. Adkinson NF Jr, Eggleston PA, Eney D, Goldstein EO, Schuberth KC, Bacon JR, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997;336:324-31.